New Findings Further Link Januvia, Byetta to Pancreatitis, Parker Waichman LLP Continues To Offer Legal Consultations to Individuals who Took Diabetes Drugs

According to a new study published in JAMA Internal Medicine, adults with Type 2 diabetes taking medications such as Januvia and Byetta may have double the risk for developing acute pancreatitis; this latest study adds to the existing body of research linking these GLP-1 based therapies to pancreatitis and pancreatic cancer. Complications of pancreatitis, or inflammation of the pancreas, include pancreatic cancer, kidney failure and other serious consequences.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Sonal Singh, assistant professor of medicine at Johns Hopkins University in Baltimore and author of the study, said that this translates to a two-fold increased risk after adjusting for variable that may increase a patient’s risk for pancreatitis.

New York, New York (PRWEB) February 27, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is warning consumers about the risks associated with using the Type 2 diabetes medications Januvia and Byetta. According to a new study published online on February 25th in JAMA Internal Medicine, adults with Type 2 diabetes who take glucagonlike peptide 1 (GLP-1)–based therapies such as Januvia (sitagliptin) and Byetta (exenatide) may be twice as likely to develop pancreatitis. This latest study supports previous findings linking the drugs to pancreatitis, which is inflammation of the pancreas.

“This research helps confirm previous reports linking Januvia and Byetta to pancreatitis,” says Parker Waichman LLP. “Anyone who was diagnosed with pancreatitis, pancreatic cancer or thyroid cancer after taking Januvia or Byetta should contact our firm to find out more about their legal rights.” The national personal injury law firm offers free legal advice to patients taking allegedly defective medical devices and drugs, including Januvia and Byetta.

According to Bloomberg, the study analyzed 1,268 patients with diabetes who had been hospitalized with pancreatitis and compared them with a control group who did not have pancreatitis. In the group with pancreatitis, 87 patients had filled a prescription for Byetta or Januvia versus 58 in the control group. Sonal Singh, assistant professor of medicine at Johns Hopkins University in Baltimore and author of the study, said that this translates to a two-fold increased risk after adjusting for variable that may increase a patient’s risk for pancreatitis.

Singh told Bloomberg News that “This is the first real study to give an estimate of what the risk is, until now we just had a few case reports.” In 2011, the journal Gastroenterology published a study showing that Januvia and Byetta users may have a 6-fold increased risk of pancreatitis as well as an increased risk for pancreatic cancer. The researchers also found a significantly higher rate of thyroid cancer among patients taking Byetta.

Bloomberg reports that GLP-1 based therapies such as Januvia and Byetta have raised concerns about damage to the pancreas since 2007, when the U.S. Food and Drug Administration (FDA) said that it received a high number of reports of pancreatitis linked to the use of Byetta. In 2009, a similar warning was issued for Januvia.

Parker Waichman LLP continues to offer free legal consultations to victims of Januvia and Byetta injuries, including pancreatitis, pancreatic cancer and thyroid cancer. If you or a loved one were diagnosed with pancreatitis, pancreatic cancer or thyroid after taking Januvia or Byetta, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com


Contact

  • Gary Falkowitz
    Parker Waichman LLP
    1-800-529-4636
    Email
Follow us on: Contact's Facebook Contact's Twitter Contact's LinkedIn Contact's Google Plus